Endothelial SOCS3 maintains homeostasis and promotes survival in endotoxemic mice

Nina Martino,Ramon Bossardi Ramos,Shuhan Lu,Kara Leyden,Lindsay Tomaszek,Sudeshna Sadhu,Gabrielle Fredman,Ariel Jaitovich,Peter A. Vincent,Alejandro P. Adam
DOI: https://doi.org/10.1101/2020.12.28.424586
2020-12-28
Abstract:Abstract SOCS3 is the main inhibitor of the JAK/STAT3 pathway. This pathway is activated by interleukin 6 (IL-6), a major mediator of the cytokine storm during shock. To determine its role in the vascular response to shock, we challenged mice lacking SOCS3 in the adult endothelium (SOCS3 iEKo ) with a non-lethal dose of lipopolysaccharide (LPS). SOCS3 iEKo mice died 16-24 hours post-injection after severe kidney failure. Loss of SOCS3 led to an LPS-induced type I interferon-like program, and high expression of pro-thrombotic and pro-adhesive genes. Consistently, we observed intraluminal leukocyte adhesion and NETosis, as well as retinal venular leukoembolization. Notably, heterozygous mice displayed an intermediate phenotype, suggesting a gene dose effect. In vitro studies were performed to study the role of SOCS3 protein levels in the regulation of the inflammatory response. In HUVEC, pulse-chase experiments showed that SOCS3 protein has a half-life below 20 minutes. Inhibition of SOCS3 ubiquitination and proteasomal degradation leads to protein accumulation and a stronger inhibition of IL-6 signaling and barrier function loss. Together, our data demonstrates that the regulation of SOCS3 protein levels is critical to inhibit IL-6-mediated endotheliopathy during shock and provides a promising new therapeutic avenue to prevent MODS though stabilization of endothelial SOCS3. Graphical abstract
What problem does this paper attempt to address?